November 2024 | AIChE

You are here

November 2024

NICE backs Pfizer's Elrexfio for multiple myeloma

The National Institute for Health and Care Excellence has recommended Pfizer's Elrexfio for patients with relapsed and refrac - More -

Guselkumab shows efficacy for plaque psoriasis

The phase 3b SPECTREM trial demonstrated that Tremfya, or guselkumab, achieved the primary endpoint, with 74.2% of patients r - More -

ReiThera's process boosts vaccine production efficiency

ReiThera has developed an intensified manufacturing process that could accelerate vaccine production during health emergencie - More -

AI offers new possibilities in protein design

AI has evolved to compose DNA, enabling scientists to design new proteins through advanced gene editing techniques. - More -

Human activities are fueling a rise in methane emissions

Methane emissions have risen faster over the past five years than in any other time in historical record, new research finds. - More -

Chemists achieve breakthrough in molecule synthesis

Chemists have successfully synthesized anti-Bredt olefins, or ABOs, molecules previously considered too unstable to exist, ch - More -

Merck buys Modifi Biosciences for $1.3B to boost oncology

Merck has acquired Modifi Biosciences, a Yale University oncology spinout, for $1.3 billion. - More -

LyondellBasell to close Houston refinery in early 2025

LyondellBasell will begin shuttering its 263,776 barrel-per-day Houston oil refinery in early 2025, adding to the growing lis - More -

Pages